These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antacids and drug trials for duodenal ulcer. Prizont R; Fredd SB Lancet; 1989 Apr; 1(8643):896. PubMed ID: 2564965 [No Abstract] [Full Text] [Related]
4. Histamine H2-receptor antagonists in the treatment of duodenal ulcers. Bank S; Barbezat GO; Novis BH; Tim LO; Odes HS; Helman C; Narunsky L; Duys PJ; Marks IN S Afr Med J; 1976 Oct; 50(44):1781-5. PubMed ID: 11564 [TBL] [Abstract][Full Text] [Related]
5. Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Deakin M; Williams JG Drugs; 1992 Nov; 44(5):709-19. PubMed ID: 1280563 [TBL] [Abstract][Full Text] [Related]
6. [Multi-center double-blind clinical trial of ranitidine in the treatment of stomach and duodenal ulcers]. Gibiński K; Nowak A; Gabrylewicz A; Laszewicz W; Hasik J; Klincewicz H; Pokora J; Czarnecki J; Kosecki J; Pachlewski J Pol Arch Med Wewn; 1982; 68(3):117-24. PubMed ID: 6133269 [No Abstract] [Full Text] [Related]
7. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy. Lima M; Holdcroft C Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal. Lam SK; Lai CL; Lee LN; Fok KH; Ng MM; Siu KF Dig Dis Sci; 1985 Jan; 30(1):45-51. PubMed ID: 2856903 [TBL] [Abstract][Full Text] [Related]
9. Today's treatment of chronic duodenal ulcer. H2 antagonists and the role of surgery. Clark CG Practitioner; 1983 Apr; 227(1378):543-6. PubMed ID: 6134276 [No Abstract] [Full Text] [Related]
10. Response to "H2-receptor antagonists and duodenal ulcer recurrence". Kurata JH; Nogawa AN; Koch GG Am J Gastroenterol; 1988 Dec; 83(12):1427-9. PubMed ID: 2904219 [No Abstract] [Full Text] [Related]
11. The H2-receptor antagonist era in duodenal ulcer disease. Marks IN Yale J Biol Med; 1992; 65(6):639-48;discussion 689-92. PubMed ID: 1364125 [TBL] [Abstract][Full Text] [Related]
12. Peptic ulcer. A follow-up study. Bank L; Wright JP; Lucke W; Marks IN J Clin Gastroenterol; 1986 Jun; 8(3 Pt 2):381-4. PubMed ID: 2876024 [TBL] [Abstract][Full Text] [Related]
13. Effect of H2 antagonists on outcome of simple closure for perforated duodenal ulcer. Koh KB; Chang KW Singapore Med J; 1992 Oct; 33(5):472-3. PubMed ID: 1360708 [TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy of duodenal ulcer with H2-receptor antagonists: a re-appraisal of the meta-analysis of Palmer et al. Koch GG; Kurata JH; Nogaway AN Aliment Pharmacol Ther; 1991 Aug; 5(4):441-7. PubMed ID: 1685676 [No Abstract] [Full Text] [Related]
19. Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing. Reynolds JC Ann Intern Med; 1989 Jul; 111(1):7-14. PubMed ID: 2567589 [TBL] [Abstract][Full Text] [Related]
20. Women and duodenal ulcer. Bianchi Porro G; Prada A; Petrillo M; Lazzaroni M Br Med J (Clin Res Ed); 1981 Jul; 283(6285):235. PubMed ID: 6114771 [No Abstract] [Full Text] [Related] [Next] [New Search]